Latest Regulatory Milestones News

Aguia Resources’ Brazilian subsidiary has achieved a key regulatory milestone with official fertiliser registration, enabling commercial sales of its PAMPAFOS phosphate product in Brazil’s large agricultural market.

Imricor Medical Systems has submitted its NorthStar Mapping System for FDA pediatric label expansion, aiming to accelerate adoption in over 250 US children’s hospitals and broaden its commercial footprint.

Vitrafy Life Sciences has announced the completion of Phase II testing of a platelet cryopreservation study with the U.S. Army Institute of Surgical Research, showing consistent results for the legacy wash-based protocol and encouraging outcomes for an innovative no-wash approach.

National Storage REIT (ASX:NSR) has confirmed satisfaction of key foreign investment conditions for its proposed acquisition by a Brookfield-GIC consortium, with securityholder meetings scheduled for mid-April.

Energy Transition Minerals Ltd (ASX:ETM) has obtained Foreign Direct Investment approval from the Spanish Government, a key regulatory milestone enabling the completion of its acquisition of the Penouta Tin-Tantalum Mine in Spain. The company anticipates finalising the acquisition this quarter, pending mining licence transfers.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

NH3 Clean Energy has entered a pivotal phase in its WAH2 Project development, partnering with global engineering giant Linde and progressing funding discussions to secure up to A$567 million. This collaboration aims to reduce capital and operational risks as the project moves closer to a final investment decision.

Everest Metals Corporation has reported promising metallurgical test results for its Mt Edon Critical Mineral Project, alongside submitting a key Mining Proposal to regulators, signalling progress toward commercial development.

Paladin Energy faces a judicial review application from the Métis Nation–Saskatchewan contesting the recent environmental approval for its Patterson Lake South Project. The legal challenge alleges insufficient Indigenous consultation and seeks to halt project progress.

Optiscan Imaging Ltd has taken a significant step towards commercialising its InSpecta® veterinary imaging device in the US by submitting a regulatory dossier to the FDA. This milestone not only initiates formal review but also sets the stage for broader clinical adoption and future device approvals.

Papua New Guinea’s Conservation and Environment Protection Authority has approved an updated Environment Permit for Geopacific Resources’ Woodlark Gold Project, enabling increased throughput and signalling strong government backing ahead of a key feasibility study.

Alterity Therapeutics has secured encouraging regulatory feedback from the FDA on its ATH434 Phase 3 program for Multiple System Atrophy, marking a critical step towards pivotal trial initiation.